# Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali

> **NCT06413108** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 167 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** TB31F
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT06413108
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-12
- **Primary completion:** 2026-01-16
- **Final completion:** 2026-01-16
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2026-01-22

## Collaborators

- Malaria Research and Training Center, Bamako, Mali
- London School of Hygiene and Tropical Medicine

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413108, "Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT06413108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*